The North America molecular point of care diagnostics market is projected to register a CAGR of 14.50% during the forecast period, 2019-2028. The region boasts of several technological innovations in terms of molecular diagnostics enhancement. Such advanced research and development projects are prioritizing genetics and pharmacogenomics, which have further improved the understanding of the biology of several types of cancer, inherited diseases, and infectious diseases.
NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET FORECAST 2019-2028
North America Molecular Point of Care Diagnostics Market by Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, Other) by Product (Assays, Instruments, Software) by Application (Infectious Disease, Oncology, Prenatal, Others) by End-user (Hospitals, Clinics, Diagnostics Centres, Others) and by Geography.
The North America molecular point of care diagnostics market is projected to register a CAGR of 14.50% during the forecast period, 2019-2028. The region boasts of several technological innovations in terms of molecular diagnostics enhancement. Such advanced research and development projects are prioritizing genetics and pharmacogenomics, which have further improved the understanding of the biology of several types of cancer, inherited diseases, and infectious diseases.
To know more about this report, request a free sample copy
The countries analyzed for market growth in the North America molecular point of care diagnostics market are the United States and Canada. The US dominated the market in 2018, which is accredited to the large-scale investments in the co-development of targeted therapeutics and molecular diagnostics. Further, in the United States, the smooth functioning of the market, in terms of approval based on the drug-diagnostics co-development model, has led to enhanced demands for molecular diagnostics with coverage. The rising geriatric population, growing prevalence of chronic diseases like cancer, cardiovascular diseases, and diabetes, have driven the adoption of molecular diagnostics in the field of precision medicine. The optimization of multiplexing capabilities and technological advancements have further revolutionized the molecular diagnostics industry. Many leading manufacturers in the US have implemented various strategies in order to register their presence in the US market. The strategic partnerships between distributors and manufacturers have strengthened the growth of the US market, in comparison to other countries. The other important factors that impact the market growth prospects include, demand for consolidation of diagnostic testing and favorable research funding for further developments.
Abbott Laboratories is a pharmaceutical company that manufactures, develops, and markets healthcare products. The company offers neuromodulation devices, diagnostic systems, medical devices, etc. and supplies its products to healthcare facilities, commercial laboratories, etc. The company has its presence in China, Germany, the US, the Netherlands, Japan, Switzerland, India, etc. and its headquarters in Abbott Park, Illinois, the US. As of March 2020, the company got its Emergency Use Authorization (EUA) from the US Food and Drug Administration, for the molecular test of COVID-19.
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- MARKET DEFINITION
- KEY DRIVERS
- DEMAND FROM GOVERNMENTS FOR DIAGNOSING COVID-19 POSITIVE PATIENTS
- RISE IN DEMAND FOR NON-INVASIVE DIAGNOSIS
- GROWTH IN THE NUMBER OF DISEASES
- FUNDING FOR RESEARCH AND DEVELOPMENT
- TECHNOLOGICAL ADVANCEMENTS IN THE MARKET
- KEY RESTRAINTS
- HIGH CAPITAL REQUIREMENT
- LACK OF HIGH COMPLEXITY TESTING CENTERS
- KEY ANALYTICS
- KEY INVESTMENT INSIGHTS
- PORTER’S FIVE FORCE ANALYSIS
- BUYER POWER
- SUPPLIER POWER
- SUBSTITUTION
- NEW ENTRANTS
- INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- REGULATORY FRAMEWORK
- MARKET BY TECHNOLOGY
- POLYMERASE CHAIN REACTION
- REAL TIME PCR
- DIGITAL PCR
- ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
- OTHER
- POLYMERASE CHAIN REACTION
- MARKET BY PRODUCT
- ASSAYS
- INSTRUMENTS
- SOFTWARE
- MARKET BY APPLICATION
- INFECTIOUS DISEASE
- RESPIRATORY
- HOSPITAL ACQUIRED INFECTIONS
- SEXUALLY TRANSMITTED INFECTIONS
- GASTRO INTESTINAL INFECTIONS
- ONCOLOGY
- PRENATAL
- OTHERS
- INFECTIOUS DISEASE
- MARKET BY END-USER
- HOSPITALS
- CLINICS
- DIAGNOSTICS CENTRES
- OTHERS
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- UNITED STATES
- CANADA
- NORTH AMERICA
- COMPANY PROFILES
- ABBOTT LABORATORIES
- ABACUS DIAGNOSTICA
- BIOMÉRIEUX SA
- BIOCARTIS NV
- DANAHER CORPORATION
- DIASORIN SPA
- BIO-RAD
- F HOFFMANN-LA ROCHE AG
- LUMINEX CORPORATION
- HOLOGIC INC
- MESA BIOTECH
- SPARTAN BIOSCIENCES INC
- QUANTUMDX GROUP LTD
- QUIDEL CORPORATION
- QIAGEN NV
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – MOLECULAR POINT OF CARE DIAGNOSTICS
TABLE 2: EMERGENCY USE AUTHORISATION FOR DIAGNOSTICS BY FDA
TABLE 3: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 5: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 7: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 8: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 9: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 10: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 12: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 14: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 15: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 16: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
LIST OF FIGURES
FIGURE 1: KEY INVESTMENT INSIGHTS
FIGURE 2: PORTER’S FIVE FORCE ANALYSIS
FIGURE 3: VALUE PROPOSITION – LABORATORY, IMMUNOASSAY, AND MOLECULAR POC DIAGNOSTIC
FIGURE 4: OPPORTUNITY MATRIX
FIGURE 5: VENDOR LANDSCAPE
FIGURE 6: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2018
FIGURE 7: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
FIGURE 8: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PCR TECHNOLOGY, IN 2018
FIGURE 9: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REAL TIME PCR, 2019-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIGITAL PCR, 2019-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHER, 2019-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2018
FIGURE 14: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ASSAYS, 2019-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INSTRUMENTS, 2019-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SOFTWARE, 2019-2028 (IN $ MILLION)
FIGURE 17: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2018
FIGURE 18: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
FIGURE 19: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY INFECTIOUS DISEASE, IN 2018
FIGURE 20: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY RESPIRATORY, 2019-2028 (IN $ MILLION)
FIGURE 21: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL ACQUIRED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 22: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SEXUALLY TRANSMITTED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 23: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GASTRO INTESTINAL INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 24: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ONCOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 25: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRENATAL, 2019-2028 (IN $ MILLION)
FIGURE 26: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 27: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2018
FIGURE 28: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITALS, 2019-2028 (IN $ MILLION)
FIGURE 29: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY CLINICS, 2019-2028 (IN $ MILLION)
FIGURE 30: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIAGNOSTIC CENTRES, 2019-2028 (IN $ MILLION)
FIGURE 31: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 32: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 33: UNITED STATES MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 34: CANADA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- UNITED STATES
- CANADA
- NORTH AMERICA
- MARKET BY TECHNOLOGY
- POLYMERASE CHAIN REACTION
- REAL TIME PCR
- DIGITAL PCR
- ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
- OTHER
- POLYMERASE CHAIN REACTION
- MARKET BY PRODUCT
- ASSAYS
- INSTRUMENTS
- SOFTWARE
- MARKET BY APPLICATION
- INFECTIOUS DISEASE
- RESPIRATORY
- HOSPITAL ACQUIRED INFECTIONS
- SEXUALLY TRANSMITTED INFECTIONS
- GASTRO INTESTINAL INFECTIONS
- ONCOLOGY
- PRENATAL
- OTHERS
- INFECTIOUS DISEASE
- MARKET BY END-USER
- HOSPITALS
- CLINICS
- DIAGNOSTICS CENTRES
- OTHERS
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.